Search
Clene Inc.
CLNNAdd to Watchlist
4.290USD
-0.090-2.05%
Close 09-23 16:00（ET）
54.83MMarket Cap
LossP/E TTM
About Clene Inc. Company
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Clene Inc. Profile
Ticker SymbolCLNN
Company nameClene Inc
IPO dateAug 27, 2018
CEOEtherington (Robert)
Number of employees75
Security typeOrdinary Share
Fiscal year-endAug 27
Address6550 South Millrock Drive, Suite G50
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84121
Phone18016769695
Websitehttps://clene.com/
Ticker SymbolCLNN
IPO dateAug 27, 2018
CEOEtherington (Robert)
Company Executives of Clene Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Prof. Matthew Kiernan, Ph.D.
Prof. Matthew Kiernan, Ph.D.
Independent Director
Independent Director
427.00
--
Prof. Matthew Kiernan, Ph.D.
Prof. Matthew Kiernan, Ph.D.
Independent Director
Independent Director
427.00
--
Prof. Matthew Kiernan, Ph.D.
Prof. Matthew Kiernan, Ph.D.
Independent Director
Independent Director
427.00
--
Mr. Jonathon T. Gay
Mr. Jonathon T. Gay
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
FAQs
Who are the top five shareholders of Clene Inc.?
The top five shareholders of Clene Inc. are: Mr. Mark Mortenson
How many institutions hold shares of Clene Inc. (CLNN)?
As of 2026Q1, 72 institutions hold shares of Clene Inc., with a combined market value of approximately 2.19M, accounting for 17.18% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -35754.00.